FREEDOM OF INFORMATION

REF: 2026-35
Subject: Diffuse Large B Cell Lymphoma (DLBCL)

Dear Sir/Madam,

Thank you for your email dated **13/01/2026** where you requested information about **Diffuse Large B Cell Lymphoma (DLBCL).**

The information you requested is enclosed.

Question	Answer
Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?	7
Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?	6
Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:	
• R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)	9
• R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)	0
• Pola-BR (polatuzumab vedotin with rituximab and bendamustine)	<5
• Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)	7
• R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)	0
• R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)	0
• R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)	<5

• (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)	0
• R-GemOX (rituximab, gemcitabine and oxaliplatin)	0
• Axicabtagene ciloleucel	0
• Tisagenlecleucel	0
• Epcoritamab	0
• Loncastuximab tesirine	0
• Glofitamab	0
• Any other SACT	0
• Stem cell transplant or bone marrow transplant (autologous or allogeneic)	0
Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):	
• Axicabtagene ciloleucel (Yescarta)	0
• Tisagenlecleucel	0
• Pola-BR (polatuzumab vedotin with rituximab and bendamustine)	<5
• R-GemOX (rituximab, gemcitabine and oxaliplatin)	0
• Stem cell transplant or bone marrow transplant (autologous or allogeneic)	0
• Glofitamab	0
• Any other treatments	0
Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)?	0
Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:	
• CAR-T Therapy (E.g. Axicabtagene ciloleucel)	0
• Stem cell transplant or bone marrow transplant (autologous or allogeneic)	0
• Any other treatment	0

If you have any queries or concerns please do not hesitate to contact the Freedom of Information Department. It would be helpful to quote the above reference number in any future communication.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to The Chief Executive, Bolton NHS Foundation Trust, The Royal Bolton Hospital, Minerva Road, Farnworth, Bolton. BL4 0JR.

If you are not content with the outcome of your complaint you may apply directly to the Information Commissioner. Generally the Information Commissioner cannot make a decision unless you have exhausted the complaints procedure provided by Bolton NHS Foundation Trust. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire. SK9 5AF.

The information supplied to you continues to be protected by the Copyright Design and Patents Act 1998. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other reuse, for example commercial publication requires the permission of the Trust. You must ensure you gain the Trust permission before reproducing any third party information.

Yours sincerely,

Information Governance Department

Bolton NHS Foundation Trust
01204 390861
FOI@boltonft.nhs.uk
Informatics Building | Opposite N Block | Royal Bolton Hospital

Improving care,
transforming lives...for a better Bolton

Improving care,
transforming lives...for a better Bolton